Panbela Therapeutics Return on Equity

Panbela Therapeutics (PBLA) currently reports a ROE of 153.59%. That is above the Technology sector average of 47.48%. Use the charts on this page to explore Panbela Therapeutics's ROE history and peer comparisons.

Panbela Therapeutics's ROE of 153.59% is higher than the Technology sector average of 47.48%. That is roughly 223.5% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Panbela Therapeutics's current 153.59% should be judged against Technology norms (sector average: 47.48%) and against PBLA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 153.59%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Technology average is 47.48%. From there, open related valuation or income-statement pages for Panbela Therapeutics, and consider following PBLA for alerts when major investors trade the stock.

Panbela Therapeutics is classified in the Technology sector. On ROE, it currently shows 153.59% versus a sector average near 47.48%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Technology are usually more informative than comparing PBLA with unrelated industries.